Combination therapy for the treatment of neovascular age-related macular degeneration

Current Opinion in Ophthalmology

Volumn 24, Issue 3, 2013, Pages 233-238

  Englander, Miriam ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antiplatelet Derived Growth Factor; Combination Treatment; Neovascular Amd; Radiation Therapy; Triple Therapy

Indexed keywords

APTAMER; BEVACIZUMAB; DEXAMETHASONE; FOVISTA; RANIBIZUMAB; STEROID; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

DRUG EFFICACY; DRUG SAFETY; HUMAN; MONOTHERAPY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; REVIEW; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; GLUCOCORTICOIDS; HUMANS; PHOTOCHEMOTHERAPY; PLATELET-DERIVED GROWTH FACTOR; RADIOTHERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84876282346     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32835f8eaa     Document Type: Review

References (26)

1. Lassota N. Clinical and histological aspects of CNV formation: studies in an animal model. Acta Ophthalmol 2008; 86 (Thesis 2):1-24.
2. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45:195-214.
3. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112:301-304.
4. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 2003; 121:1392-1396.
5. Kwok AKH, Lai TYY, Chan CWN, et al. Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol 2002; 86:892-897.
6. Obata R, Yanagi Y, Kami J, et al. Polypoidal choroidal vasculopathy and retinochoroidal anastomosis in Japanese patients eligible for photodynamic therapy for exudative age-related macular degeneration. Jpn J Ophthalmol 2006; 50:354-360.
7. Chen SJ, Cheng CY, Peng KL, et al. Prevalence and associated risk factors of age-related macular degeneration in an Elderly Chinese Population in Taiwan: The Shihpai Eye Study. Invest Ophthalmol Vis Sci 2008; 49:3126-3133.
8. Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in Patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32:1453-1464. The EVEREST trial reported that verteporfin PDT combined with ranibizumab 0.5mg or alone was superior to ranibizumab monotherapy in achieving complete regression of polyps in this 6-month study in patients with symptomatic macular polypoidal choroidal vasculopathy.
9. Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration. Ophthalmology 2012; 119:1001-1010. The DENALI trial investigated whether verteporfin standard or reduced fluence in combination with ranibizumab administered with a loading phase followed by PRN was noninferior to fixed monthly ranibizumab injections. Noninferiority of either combination regimen to monthly ranibizumab injections was not demonstrated; however, both combination regimens resulted in BCVA gains at month 12.
10. Rouvas AA, Papakostas TD, Vavvas D, et al. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina 2009; 29:536-544.
11. Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL). Full Text View -ClinicalTrials.gov. clinicaltrialsgov. http://clinicaltrials.gov/ct2/show/study/NCT00492284. [Accessed 2 November 2012]. The RADICAL study result showed that triple combination therapy significantly decreased the number of retreatment visits required over 2 years. Of the four treatment groups, the triple therapy half-fluence group had the fewest retreatment visits compared with ranibizumab monotherapy.
12. Chakravarthy U, MacKenzie G. External beam radiotherapy in exudative agerelated macular degeneration: a pooled analysis of phase I data. Br J Radiol 2000; 73:305-313.
13. Jaakkola A, Heikkonen J, Tommila P, et al. Strontium plaque brachytherapy for exudative age-related macular degeneration. Three-year results of a randomized study. Ophthalmology 2005; 112:567e1-573e1.
14. Evans JR, Sivagnanavel V, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2010; 5:CD004004.
15. Ávila MP, Farah ME, Santos A, et al. Three-year safety and vision results of epimacular 90Strontium/90Yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina 2012; 32:10-18. This study revived interest in radiation therapy combined with anti-VEGF agents because of the outstanding results. These results were not replicated in larger phase 3 studies.
16. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145:239-248.
17. Canton VM, Quiroz-Mercado H, Velez-Montoya R, et al. 24-Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes. Ophthalmic Surg Lasers Imaging 2012; 43:20-24.
18. Moshfeghi AA, Morales-Canton V, Quiroz-Mercado H, et al. 16 Gy lowvoltage X-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a 'radiation-first' strategy. Br J Ophthalmol 2012; 96:1320-1324.
19. INTREPID -IRay Plus Anti-VEGF Treatment For Patients With Wet AMD. Full Text View -ClinicalTrials.gov. clinicaltrialsgov. http://clinicaltrials.gov/ct2/ show/NCT01016873?termoraya&rank2. [Accessed 2 October 2012].
20. www.orayainc.com/wp-content/uploads/2012/05/Oraya-INTREPID-Press-Release. pdf. orayainc.com.
21. http://www.orayainc.com/wp-content/uploads/2012/05/Oraya-INTREPID-Press- Release.pdf. [Accessed 2 October 2012]. The INTREPID clinical trial of radiation therapy met its primary endpoint of reduction in anti-VEGF injections for patients with wet AMD. The INTREPID study is the first, sham-controlled, double-masked trial to evaluate the effectiveness and safety of a one-timeradiation therapy in conjunction with as-needed anti-VEGF injections for the treatment of wet AMD.
22. Colucciello M. Intravitreal bevacizumab and triamcinolone acetonide combination therapy for exudative neovascular age-related macular degeneration: shortterm optical coherence tomography results. J Ocul Pharmacol Ther 2008; 24:15-24.
23. Jonas JB, Libondi T, Golubkina L, et al. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration. Acta Ophthalmol 2009; 88:630-634.
24. Wa°gsater D, Zhu C, Bjorck HM, Eriksson P. Effects of PDGF-C and PDGF-D on monocyte migration and MMP-2 and MMP-9 expression. Atherosclerosis 2009; 202:415-423.
25. Hou X, Kumar A, Lee C, et al. PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets. Proc Natl Acad Sci USA 2010; 107:12216-12221.
26. Ophthotech's Novel Anti-PDGF Combination Agent FovistaTM Demonstrated Superior Efficacy over Lucentis1 Monotherapy in Large Controlled Wet AMD Trial. Business Wire. businesswire.com. http://www.businesswire.com/news/home/ 20120613005333/en/Ophthotech%E2%80%99s-Anti-PDGFCombination-Agent-FovistaTM- Demonstrated-Superior. [Accessed 2 October 2012].